Q-omics provides the consensus-scored RPLP1P5 profile across patient tissues and cancer cell-line models. RPLP1P5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPLP1P5 is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, RPLP1P5 RNA expression shows 10,200 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight KIRC, KIRP, and READ as cancer lineages where RPLP1P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPLP1P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPLP1P5 survival associations across molecular data types. RPLP1P5 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPLP1P5 RNA expression–survival associations across cancer types. High RPLP1P5 expression shows unfavorable associations in KICH and LAML, but favorable associations in KIRC, UCEC, UVM and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPLP1P5 RNA expression.
This table summarizes RPLP1P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPLP1P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPLP1P5 shows lower tumor expression in KIRP, KICH and CHOL and higher tumor expression in HNSC, COAD and LUSC. The KIRP box plot shows higher RPLP1P5 RNA expression in normal versus tumor tissue (log2 FC = −2.082, t-test p < 0.001).
This table shows molecular features associated with RPLP1P5 in patient tissues and cancer cell lines. In patient samples, RPLP1P5 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
